secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0001193125-24-163507
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven shareholders approve 2.9M share increase in equity plan and officer exculpation amendment
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2020 Equity Incentive Plan, increasing authorized shares by 2,900,000.
- Certificate of Incorporation amended to limit officer liability for monetary damages under Delaware law.
- Class I directors Mika Derynck (36.4M for) and Rishi Gupta (37.4M for) elected to 2027 annual meeting.
- Deloitte & Touche LLP ratified as independent auditor for FY 2024 with 42.9M votes for.
- All proposals passed; broker non-votes 4.6M on director elections and other items.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524163507/0001193125-24-163507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312524163507/d853800d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-163507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer